Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | DAO | P14920 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | DDO | Q99489 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66296 | 0.79 | NOS1 (0.44) | CA12CA9PARP1NPC1RAB9A | |
| SCHEMBL23278130 | 0.79 | CA12 (0.42) | CA12CA9PARP1NPC1RAB9A | |
| SCHEMBL5142221 | 0.76 | PARP1 (0.59) | CA12CA9PARP1NPC1RAB9A | |
| SCHEMBL12778711 | 0.76 | CA12 (0.40) | CA12CA9PARP1NPC1RAB9A | |
| SCHEMBL8956424 | 0.76 | TDP1 (0.33) | PARP1NPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL6139156 | 0.76 | PARP1 (0.41) | PARP1NPC1RAB9ADAOALDH1A1 | |
| SCHEMBL9305473 | 0.76 | ACHE (0.43) | PARP1RAB9ADAOALDH1A1TDP1 | |
| SCHEMBL9306736 | 0.76 | CA12 (0.40) | CA12CA9PARP1NPC1RAB9A | |
| SCHEMBL20479323 | 0.76 | PDPK1 (0.43) | CA12CA9PARP1PTGESHCAR1 | |
| SCHEMBL31122397 | 0.76 | NUDT1 (0.48) | CA12CA9PARP1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421213-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-08-23 | — | — | US | disclosed |
| US-20160074412-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-03-17 | — | — | US | disclosed |
| US-9155742-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-20150164908-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-06-18 | — | — | US | disclosed |
| US-8999997-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-07 | — | — | US | disclosed |
| EP-2579877-B1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2014-08-13 | — | — | EP | disclosed |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-01-16 | — | — | US | disclosed |
| US-8552004-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-10-08 | — | — | US | disclosed |
| EP-2579877-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2013-04-17 | — | — | EP | disclosed |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164908-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | CA12 3011/4885CA9 925/4885PARP1 2289/4885 |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | CA12 3011/4885CA9 925/4885PARP1 2289/4885 |
| US-20160074412-A1 | Chemical Compounds | CYP2C19, ABCG2, CYP2C9 | CA12 3011/4885CA9 925/4885PARP1 2289/4885 |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | CA12 3011/4885CA9 925/4885PARP1 2289/4885 |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | CA12 3011/4885CA9 925/4885PARP1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.